Literature DB >> 8243585

Types and time course of the alterations induced in monkey blink movements by botulinum toxin.

J D Porter1, R S Baker, M W Stava, I B Gaddie, J K Brueckner.   

Abstract

The alterations induced in eyelid movement metrics subsequent to unilateral injections of botulinum toxin type A into the orbicularis oculi muscle were studied in chronic alert monkeys using the search coil technique. Botulinum toxin caused rapid paralysis of blinks in the treated eyelid. The amplitude and peak velocity of blinks generated by this eyelid remained at or below 20% of that of the fellow, untreated eyelid for 10-20 days. Blink amplitude gain increased linearly thereafter, attaining control values by 40-60 days after injection. Recovery of blink peak velocity was slower. The adaptive alterations in blink duration that were observed during the acute phase of toxin paralysis suggest that the mechanisms responsible for blink reflex plasticity may produce bilateral adjustments in eyelid function. Taken together, these data establish a quantitative data base that can be exploited in order to: (1) better understand the neural adaptive mechanisms that operate during eyelid movements and (2) allow quantitative comparisons between current treatment protocols that employ botulinum toxin and protocols that may lead to improvements in the treatment of chronic eyelid spasm (blepharospasm).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243585     DOI: 10.1007/bf00230440

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  28 in total

1.  Botulinum-induced changes in monkey eyelid muscle. Comparison with changes seen in extraocular muscle.

Authors:  J D Porter; S Strebeck; N F Capra
Journal:  Arch Ophthalmol       Date:  1991-03

2.  Contralateral early blink reflex in patients with facial nerve palsy: indication for synaptic reorganization in the facial nucleus during regeneration.

Authors:  W Nacimiento; K Podoll; M B Graeber; R Töpper; E Möbius; H Ostermann; J Noth; G W Kreutzberg
Journal:  J Neurol Sci       Date:  1992-06       Impact factor: 3.181

3.  Eyelid movements in facial paralysis.

Authors:  P A Sibony; C Evinger; K A Manning
Journal:  Arch Ophthalmol       Date:  1991-11

4.  Upper eyelid movements measured with a search coil during blinks and vertical saccades.

Authors:  D Guitton; R Simard; F Codère
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-12       Impact factor: 4.799

5.  [Facial reflexes].

Authors:  E KUGELBERG
Journal:  Brain       Date:  1952-09       Impact factor: 13.501

6.  Facial nerve injury and hemifacial spasm.

Authors:  B R Frueh; R A Preston; D C Musch
Journal:  Am J Ophthalmol       Date:  1990-10-15       Impact factor: 5.258

7.  Reorganization of the facial motor nucleus after peripheral nerve regeneration. An HRP study in the rat.

Authors:  L Thomander
Journal:  Acta Otolaryngol       Date:  1984 May-Jun       Impact factor: 1.494

8.  Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features.

Authors:  D Angaut-Petit; J Molgó; J X Comella; L Faille; N Tabti
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

9.  Pathophysiology of blepharospasm and oromandibular dystonia.

Authors:  A Berardelli; J C Rothwell; B L Day; C D Marsden
Journal:  Brain       Date:  1985-09       Impact factor: 13.501

10.  Blink reflex excitability cycle in hemifacial spasm.

Authors:  J Valls-Sole; E S Tolosa
Journal:  Neurology       Date:  1989-08       Impact factor: 9.910

View more
  2 in total

1.  Nonmuscle myosin IIB, a sarcomeric component in the extraocular muscles.

Authors:  Carole L Moncman; Francisco H Andrade
Journal:  Exp Cell Res       Date:  2010-03-27       Impact factor: 3.905

2.  Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle.

Authors:  Stephen P Christiansen; Brian C Anderson; Linda K McLoon
Journal:  J AAPOS       Date:  2008-02-07       Impact factor: 1.220

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.